Market Research Logo

US Acne & Rosacea Market: Industry Analysis & Outlook (2018-2022)

US Acne & Rosacea Market: Industry Analysis & Outlook (2018-2022)

Acne and Rosacea are the most common dermatological disorders affecting people in the United States. Acne is a chronic skin disorder in which the hair follicles become blocked and/or inflamed, which is most prevalent among teenagers. However, some people may suffer from acne well into their 30s and 40s even. Acne can occur in forms ranging from comedones to cystic lesions, depending upon severity.

Rosacea is a common skin condition that causes redness and visible blood vessels on the nose, cheeks, and forehead. Rosacea can occur to anyone. But it is most commonly affects adults over age 30, particularly women with fair skin. The condition of rosacea is increasingly widespread in the U.S. and affecting approximately 16 million population in the country.

Topical drugs currently dominate both markets in the U.S. Systemic medications such as oral antibiotics, hormonal agents or other drugs are also used for the treatment of acne and rosacea. The ongoing development of new drugs is expected to witness an extraordinary growth rate due to higher efficacy, convenient dosing and fewer side effects.

The increase in emotional burden due to these skin conditions is a key factor driving the growth of the market. Growing awareness regarding rosacea and acne treatment options has significantly driven the market in the U.S. Rising purchasing power and mounting healthcare expenditure has also fuelled the growth of the market in the region. Despite being common skin disorders, advancement in treatment has been limited over the past years exhibiting a great opportunity of growth in the future. The companies are developing new treatment options, in which, most products are in late-stage indicating an optimistic future for the market.

The report “U.S. Acne & Rosacea Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. market. The report profiles the key players of the market including Bausch Health Companies, Allergan, Foamix Pharmaceuticals and Sol-Gel Technologies.


1. Market Overview
1.1 Acne
1.1.1 Acne Overview
Table 1: Types of Acne
1.1.2 Causes & Symptoms of Acne
1.1.3 Classification of Severity
1.1.4 Treatment for Acne
Table 2: Treatment for Acne
1.1.5 Acne Treatment Continuum
Table 3: Acne Treatment Continuum
1.1.6 Limitations of Acne Treatments
Table 4: Limitations of Commonly Used Acne Treatments
1.2 Rosacea
1.2.1 Rosacea Overview
Table 5: Types of Rosacea
1.2.2 Symptoms and Causes of Rosacea
1.2.3 Treatment for Rosacea
Table 6: Treatment for Rosacea
2. The U.S. Acne Market
2.1 The U.S. Acne Market Forecast by Value
Table 7: The U.S. Acne Market Forecast by Value (2017-2022)
2.2 The U.S. Acne Market by Drug Type
Table 8: The U.S. Acne Market by Drug Type (2017)
2.3 The U.S. Acne Topical Drugs by Brand
Table 9: The U.S. Acne Topical Drugs by Brand (2017)
2.4 The U.S. Acne Oral Antibiotics by Brand
Table 10: The U.S. Acne Oral Antibiotics by Brand (2017)
2.5 The U.S. Acne Market Forecast by Product
2.5.1 The U.S. Minocycline Revenue Forecast
Table 11: The U.S. Minocycline Revenue Forecast (2017-2022)
2.5.2 The U.S. Retin-A Generics Revenue Forecast
Table 12: The U.S. Retin-A Generics Revenue Forecast (2017-2022)
2.5.3 The U.S. Epiduo/Epiduo Forte Revenue Forecast
Table 13: The U.S. Epiduo/Epiduo Forte Revenue Forecast (2017-2022)
2.5.4 The U.S. Aczone Revenue Forecast
Table 14: The U.S. Aczone Revenue Forecast (2017-2022)
2.5.5 The U.S. Onexton Revenue Forecast
Table 15: The U.S. Onexton Revenue Forecast (2017-2022)
2.5.6 The U.S. Solodyne Revenue Forecast
Table 16: The U.S. Solodyne Revenue Forecast (2017-2022)
2.5.7 The U.S. Oracea Revenue Forecast
Table 17: The U.S. Oracea Revenue Forecast (2017-2022)
2.5.8 The U.S. Ziana Revenue Forecast
Table 18: The U.S. Ziana Revenue Forecast (2017-2022)
2.6 The U.S. Acne Prevalence Forecast
Table 19: The U.S. Acne Prevalence Forecast (2017-2022)
2.7 The U.S. Acne Addressable Population
2.7.1 The U.S. Acne Addressable Population Forecast
Table 20: The U.S. Acne Addressable Population Forecast (2017-2022)
2.7.2 The U.S. Acne Addressable Population by Severity
Table 21: The U.S. Acne Addressable Population by Severity (2017)
2.7.3 The U.S. Acne Mild Population Forecast
Table 22: The U.S. Acne Mild Population Forecast (2017-2022)
2.7.4 The U.S. Acne Moderate Population Forecast
Table 23: The U.S. Acne Moderate Population Forecast (2017-2022)
2.7.5 The U.S. Acne Severe Population Forecast
Table 24: The U.S. Acne Severe Population Forecast (2017-2022)
2.8 The U.S. Acne Topical Treatment Population
2.8.1 The U.S. Acne Topical Treatment Population Forecast
Table 25: The U.S. Acne Topical Treatment Population Forecast (2017-2022)
2.8.2 The U.S. Acne Topical Treatment Population by Severity
Table 26: The U.S. Acne Topical Treatment Population by Severity (2017)
2.8.3 The U.S. Acne Topical Treatment Mild Population Forecast
Table 27: The U.S. Acne Topical Treatment Mild Population Forecast (2017-2022)
2.8.4 The U.S. Acne Topical Treatment Moderate Population Forecast
Table 28: The U.S. Acne Topical Treatment Moderate Population Forecast (2017-2022)
2.8.5 The U.S. Acne Severe Topical Treatment Population Forecast
Table 29: The U.S. Acne Severe Topical Treatment Population Forecast (2017-2022)
2.9 FMX101
2.9.1 The U.S. FMX-101 Drug Patient Population Forecast
Table 30: The U.S. FMX-101 Drug Patient Population Forecast (2020-2024)
2.9.2 The U.S. FMX-101 Drug Market Share Forecast
Table 31: The U.S. FMX-101 Drug Market Share Forecast (2020-2024)
2.9.3 The U.S. FMX-101 Drug Cost Forecast
Table 32: The U.S. FMX-101 Drug Cost Forecast (2020-2024)
2.9.4 The U.S. FMX-101 Drug Revenue Forecast
Table 33: The U.S. FMX-101 Drug Revenue Forecast (2020-2024)
2.10 TWIN
2.10.1 The U.S. TWIN Drug Patient Population Forecast
Table 34: The U.S. TWIN Drug Patient Population Forecast (2021-2025)
2.10.2 The U.S. TWIN Drug Market Share Forecast
Table 35: The U.S. TWIN Drug Market Share Forecast (2021-2025)
2.10.3 The U.S. TWIN Drug Cost Forecast
Table 36: The U.S. TWIN Drug Cost Forecast (2021-2025)
2.10.4 The U.S. TWIN Drug Revenue Forecast
Table 37: The U.S. TWIN Drug Revenue Forecast (2021-2025)
2.11 SIRS-T
2.11.1 The U.S. SIRS-T Drug Patient Population Forecast
Table 38: The U.S. SIRS-T Drug Patient Population Forecast (2022-2026)
2.11.2 The U.S. SIRS-T Drug Market Share Forecast
Table 39: The U.S. SIRS-T Drug Market Share Forecast (2022-2026)
2.11.3 The U.S. SIRS-T Drug Cost Forecast
Table 40: The U.S. SIRS-T Drug Cost Forecast (2022-2026)
2.11.4 The U.S. SIRS-T Drug Revenue Forecast
Table 41: The U.S. SIRS-T Drug Revenue Forecast (2022-2026)
3. The U.S. Rosacea Market
3.1 The U.S. Rosacea Market Forecast by Value
Table 42: The U.S. Rosacea Market Forecast by Value (2017-2022)
3.2 The U.S. Rosacea Total Cases Forecast
Table 43: The U.S. Rosacea Total Cases Forecast (2017-2022)
3.3 The U.S. Rosacea Market by Drug Type
Table 44: The U.S. Rosacea Market by Drug Type (2017)
3.4 The U.S. Rosacea Market by Drug Type
3.4.1 The U.S. Rosacea Market Revenue and Prescription by Drug Type
Table 45: The U.S. Rosacea Market Revenue and Prescription by Drug Type (2017)
3.4.2 The U.S. Rosacea Market Revenue and Prescription by Brand
Table 46: The U.S. Rosacea Drug Revenue and Prescription by Brand (2017)
Table 47: The U.S. Rosacea Drug Revenue Share by Brand (2017)
3.5 The U.S. Rosacea Prevalence Forecast
Table 48: The U.S. Rosacea Prevalence Forecast (2017-2022)
3.6 The U.S. Rosacea Addressable Population
3.6.1 The U.S. Rosacea Addressable Population Forecast
Table 49: The U.S. Rosacea Addressable Population Forecast (2017-2022)
3.6.2 The U.S. Rosacea Addressable Population by Severity
Table 50: The U.S. Rosacea Addressable Population by Severity (2017)
3.6.3 The U.S. Rosacea Mild Population Forecast
Table 51: The U.S. Rosacea Mild Population Forecast (2017-2022)
3.6.4 The U.S. Rosacea Moderate Population Forecast
Table 52: The U.S. Rosacea Moderate Population Forecast (2017-2022)
3.6.5 The U.S. Rosacea Severe Population Forecast
Table 53: The U.S. Rosacea Severe Population Forecast (2017-2022)
3.7 The U.S. Rosacea Topical Treatment Population
3.7.1 The U.S. Rosacea Topical Treatment Population Forecast
Table 54: The U.S. Rosacea Topical Treatment Population Forecast (2017-2022)
3.7.2 The U.S. Rosacea Topical Treatment Population by Severity
Table 55: The U.S. Rosacea Topical Treatment Population by Severity (2017)
3.7.3 The U.S. Rosacea Topical Treatment Mild Population Forecast
Table 56: The U.S. Rosacea Topical Treatment Mild Population Forecast (2017-2022)
3.7.4 The U.S. Rosacea Topical Treatment Moderate Population Forecast
Table 57: The U.S. Rosacea Topical Treatment Moderate Population Forecast (2017-2022)
3.7.5 The U.S. Rosacea Severe Topical Treatment Population Forecast
Table 58: The U.S. Rosacea Severe Topical Treatment Population Forecast (2017-2022)
3.8 FMX103
3.8.1 The U.S. FMX-103 Drug Patient Population Forecast
Table 59: The U.S. FMX-103 Drug Patient Population Forecast (2021-2025)
3.8.2 The U.S. FMX-103 Drug Market Share Forecast
Table 60: The U.S. FMX-103 Drug Market Share Forecast (2021-2025)
3.8.3 The U.S. FMX-103 Drug Revenue Forecast
Table 61: The U.S. FMX-103 Drug Revenue Forecast (2021-2025)
3.9 VERED
3.9.1 The U.S. VERED Drug Patient Population Forecast
Table 62: The U.S. VERED Drug Patient Population Forecast (2021-2025)
3.9.2 The U.S. VERED Drug Market Share Forecast
Table 63: The U.S. VERED Drug Market Share Forecast (2021-2025)
3.9.3 The U.S. VERED Drug Cost Forecast
Table 64: The U.S. VERED Drug Cost Forecast (2021-2025)
3.9.4 The U.S. VERED Drug Revenue Forecast
Table 65: The U.S. VERED Drug Revenue Forecast (2021-2025)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Youth Population
Table 66: The U.S. Acne Patients by Age (2017)
4.1.2 Rising Purchasing Power
Table 67: The U.S. GNI Per Capita (2013-2017)
4.1.3 Escalating Healthcare Expenditure
Table 68: The U.S. Healthcare Expenditure Per Capita (2013-2017)
4.1.4 Vast Market Opportunity
Table 69: The U.S. Dermatology Drugs Market (2013-2017)
4.1.5 Sedentary Lifestyle and Unhealthy Eating Habits
4.2 Key Trends & Developments
4.2.1 Growing Awareness
4.2.2 Rising Medical Tourism
4.2.3 Preference for Minimally Invasive Procedures
4.2.4 Personal Appearance Importance
4.3 Challenges
4.3.1 Entry of Generic Drugs
4.3.2 Side Effects of Acne and Rosacea Therapies
4.3.3 Tough Regulations
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
Table 70: Key Players - Revenue & Market Cap Comparison (2017)
5.1.2 Global Acne Market- Drug Comparison by Company
Table 71: Global Acne Market- Drug Comparison by Company (2017)
5.1.3 Global Late Stage Acne Market- Drug Comparison by Company
Table 72: Global Late Stage Acne Market- Drug Comparison by Company (2017)
5.1.4 Global Mid Stage Acne Market- Drug Comparison by Company
Table 73: Global Mid Stage Acne Market- Drug Comparison by Company (2017)
5.1.2 Global Rosacea Market- Drug Comparison by Company
Table 74: Global Rosacea Market- Drug Comparison by Company (2017)
6. Company Profiles
6.1 Bausch Health Companies, Inc.
6.1.1 Business Overview
Table 75: Bausch Health Companies Revenue by Segments (2017)
6.1.2 Financial Overview
Table 76: Bausch Health Companies Revenue and Net Loss (2013-2017)
6.1.3 Business Strategies
Table 77: Bausch Health Companies Research & Development Expenses (2015-2017)
6.2 Foamix Pharmaceuticals Ltd.
6.2.1 Business Overview
Table 78: Foamix Pharmaceuticals Product Pipeline (2017)
6.2.2 Financial Overview
Table 79: Foamix Pharmaceuticals Revenue and Net Income (2013-2017)
6.2.3 Business Strategies
Table 80: Foamix Pharmaceuticals R&D Expenses (2015-2017)
6.3 Allergan Plc.
6.3.1 Business Overview
Table 81: Allergan Net Revenue by Business Segments (2017)
6.3.2 Financial Overview
Table 82: Allergan Net Revenue and Net Income (Loss) (2013-2017)
6.3.3 Business Strategies
Table 83: Allergan Research and Development Expenditures (2015-2017)
6.4 Sol Gel Technologies Ltd.
6.4.1 Business Overview
Table 84: Sol Gel Technologies Ltd. Product Pipeline (2017)
6.4.2 Financial Overview
Table 85: Sol Gel Technologies Ltd. Revenue and Net Loss (2013-2017)
6.4.3 Business Strategies
Table 86: Sol Gel Technologies Ltd. Research & Development Expenses (2015-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report